#Zepatier

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

This is according to two studies of real-world use of the hepatitis C regimen.

Those who took the drug, which is included in Zepatier (grazoprevir/elbasvir), had a low rate of liver cancer during the following years.

A recent study found that transplanting such kidneys and then treating the recipient for hep C worked well.

Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

Genotype 3 of hepatitis C virus is typically difficult to treat.

More than 125,000 veterans will have received lifesaving cures by October 2018.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.

Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.